[ET Net News Agency, 4 April 2023] UBS lowered its target price for Simcere Pharma
(02096) to HK$13.4 from HK$14.2 and maintained its "buy" rating.
The research house said it rolled over its forecast to 2027E, revised down 23E/24E
revenue estimates primarily due to lower-than-expected demand for Xiannuoxin. (RC)